Trametinib for Arterial Venous Malformation

"According to clinicaltrials.gov, this medical research project is actively recruiting. The trial was published on December 1st 2020 and the most recent update occurred in February 25th 2022."

"Affirmative. Data available on clinicaltrials.gov indicates that this medical trial is presently in search of participants, with the original post being made on December 1st 2020 and most recently updated on February 25th 2022. This research requires 30 patients to be recruited from one site alone."

"This trial is actively seeking 30 individuals between the ages of 12 and 60 that have been diagnosed with a fetal abnormality. Eligible participants must also meet these additional conditions: MAP2K1 genetic testing or RAS/MAPK pathway mutation analysis (preferred but not compulsory), any necessary clinical and laboratory examinations to verify eligibility should be completed within six weeks, at least four weeks since major surgery, endocrine deficiency patients may receive appropriate doses of corticosteroids if needed, 14 days from completion of biologic therapy (or longer depending on adverse effects profile) and candidates who had undergone AVM resection or sclerotherapy can still"

"This clinical trial has regulations that stipulate the minimum age of enrolment is 12, while participants must be under 60 years old to qualify."

"Trametinib tablet has been allotted a safety score of 2 by the team at Power, due to this being a Phase 2 trial with evidence only confirming its security rather than efficacy."

"Currently, there are 92 research initiatives exploring the efficacy of Trametinib tablets. Of those trials, 6 have advanced to Phase 3. Despite being primarily conducted in Saint Louis, Missouri; this drug is being investigated at 5794 locations worldwide."